natgillin/translations-raw huggingface dataset:
ESAs are not indicated for use in this patient population. 
Uporaba ESA v tej populaciji bolnikov ni indicirana.
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. 
Pri bolnikih s kronično odpovedjo ledvic vzdrževana koncentracija hemoglobina ne sme preseči zgornje meje ciljne koncentracije hemoglobina, priporočene v poglavju 4.2.
Stretch your skin firmly by moving your thumb and fingers in opposite directions, creating an area about 5 cm (2-inches) wide. 
Kožo čvrsto raztegnite tako, da palec in prste razmaknete v nasprotni smeri in tako ustvarite približno 5 cm širok predel.
Talk with your healthcare provider about proper disposal. 
Z zdravstvenim delavcem se posvetujte o pravilnem odlaganju.
Where the same sampling duration was used, observed pharmacokinetic data and population pharmacokinetic modelling demonstrated that the pharmacokinetics of darbepoetin alfa was similar for paediatric and adult patients with CRF. 
Kjer je vzorčenje trajalo enako dolgo, so opaženi farmakokinetični podatki in modeliranje farmakokinetike populacije pokazali, da je bila farmakokinetika darbepoetina alfa pri pediatričnih in odraslih bolnikih s kronično boleznijo ledvic podobna.
Effect on tumour growth 
Vpliv na rast tumorja
If you are receiving chemotherapy 
Če dobivate kemoterapijo
Controlled clinical trials have not shown significant benefits attributable to the administration of epoetins when haemoglobin concentration is increased beyond the level necessary to control symptoms of anaemia and to avoid blood transfusion. 
Kontrolirana klinična preskušanja niso pokazala pomembnih koristi uporabe epoetinov, če koncentracija hemoglobina preseže raven, potrebno za obvladanje simptomov anemije in preprečitev transfuzij krvi.
The route of injection is the same as with r-HuEPO but your doctor will tell you how much you should take, and when, and may adjust your dose if necessary. 
Pot injiciranja je enaka kot pri r-HuEPO, zdravnik pa vam bo povedal, koliko zdravila morate uporabiti in kdaj.
Note: After you remove the pre-filled pen from your skin, the needle will be automatically covered. 
Opomba: Potem ko boste napolnjeni injekcijski peresnik odmaknili od kože, bo samodejno prekril iglo.
What should I do before I give myself a subcutaneous injection of Aranesp? 
Kaj moram narediti, preden si dam podkožno injekcijo zdravila Aranesp?
The production of erythropoietin primarily occurs in and is regulated by the kidney in response to changes in tissue oxygenation. 
Eritropoetin nastaja predvsem v ledvicah, ki ga tudi uravnavajo v odziv na spremembe v oksigenaciji tkiva.
Aranesp therapy should be discontinued approximately four weeks after the end of chemotherapy. 
Zdravljenje z zdravilom Aranesp je treba končati približno 4 tedne po koncu kemoterapije.
Do not use it if the date has passed the last day of the month shown. 
Zdravila ne uporabite, če je že pretekel zadnji dan navedenega meseca.
• Convulsions (fits and seizures) 
• konvulzije (krči in napadi)
Release button 
Spustite gumb
Injecting the solution with the air bubble is harmless. 
Injiciranje raztopine z zračnim mehurčkom ne bo škodovalo.
Your doctor, nurse or pharmacist will tell you how much Aranesp you need and how frequently it should be injected. 
Zdravnik, medicinska sestra ali farmacevt vam bo povedal, koliko zdravila Aranesp potrebujete in kako pogosto si ga morate injicirati.
Do not put the pre-filled pen back in the refrigerator once it has reached room temperature. 
Ne vračajte napolnjenega injekcijskega peresnika nazaj v hladilnik, ko je le-ta dosegel sobno temperaturo.
In all studies in rats and dogs darbepoetin alfa produced marked increases in haemoglobin, haematocrits, red blood cell counts and reticulocytes, which correspond to the expected pharmacological effects. 
V vseh študijah pri podganah in psih je darbepoetin alfa povzročil izrazito zvišanje hemoglobina, hematokrita, števila rdečih krvnih celic in retikulocitov, kar ustreza pričakovanim farmakološkim učinkom.
• 0.75 micrograms once every two weeks, or 
• 0,75 mikrogramov enkrat na dva tedna ali
Improvement in fatigue, as measured by the Functional Assessment of Cancer Therapy-fatigue (FACT-fatigue) scale, was also observed. 
Ugotovili so tudi izboljšanje utrujenosti, merjene z lestvico FACT-utrujenost (Functional Assessment of Cancer Therapy-fatigue).
A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins. 
Opravljena je bila tudi analiza podatkov na ravni bolnikov, in sicer za več kot 13.900 bolnikov z rakom (ki so dobivali kemoterapijo, radioterapijo, kombinirano kemo-radioterapijo ali nobenega zdravljenja) iz 53 kontroliranih kliničnih preskušanj z več epoetini.
Hypersensitivity reactions were also very common in the placebo groups. 
Preobčutljivostne reakcije so bile zelo pogoste tudi v skupinah s placebom.
If you experience these symptoms you should contact your doctor. 
Če se vam pojavijo takšni simptomi, se morate posvetovati z zdravnikom.
Darbepoetin alfa has five N-linked carbohydrate chains whereas the endogenous hormone and recombinant human erythropoietins (r-HuEPO) have three. 
Darbepoetin alfa ima pet N-vezanih ogljikohidratnih verig, endogeni hormon in rekombinantni humani eritropoetini (r-HuEPO) pa imajo tri.
Pharmacotherapeutic group: Anti-anaemic preparations, other anti-anaemic preparations, ATC Code: B03XA02. 
Farmakoterapevtska skupina: Zdravila za zdravljenje slabokrvnosti, druga zdravila za zdravljenje slabokrvnosti, oznaka ATC: B03XA02.
Very common: may affect more than 1 in 10 people • Allergic reactions 
Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov • alergijske reakcije
- If you have symptoms which include severe headache, drowsiness, confusion, problems with your eyesight, nausea, vomiting or fits (seizures), it could mean that you have very high blood pressure. 
- Če imate simptome, med katerimi so hud glavobol, zaspanost, zmedenost, težave z vidom, slabost v želodcu, bruhanje ali napadi krčev (konvulzije), to lahko pomeni, da imate zelo visok krvni tlak.
Supplementary iron therapy is recommended for all patients with serum ferritin values below 100 mcg/L or whose transferrin saturation is below 20%. 
Dodatno zdravljenje z železom je priporočljivo pri vseh bolnikih, ki imajo feritin v serumu pod 100 µg/l ali nasičenost transferina pod 20 %.
These serious skin rashes are often preceded by fever and/or flu-like symptoms. 
Pred takšnimi resnimi izpuščaji na koži se pogosto pojavijo zvišana telesna temperatura in/ali gripi podobni simptomi.
Pure red cell aplasia 
čista aplazija rdečih celic
In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer. 
Glede na zgoraj navedeno, je treba v nekaterih kliničnih primerih anemijo pri bolnikih z rakom prednostno zdraviti s transfuzijo krvi.
If you do not respond adequately to Aranesp, your doctor will check your dose and will inform you if you need to change doses of Aranesp. 
Če se na zdravilo Aranesp ne boste odzvali zadostno, bo zdravnik preveril vaš odmerek in vam povedal, če boste morali spremeniti odmerke zdravila Aranesp.
In a phase 1 pharmacokinetic study, following intravenous administration, an approximate 25% difference between paediatric and adult patients in the area under the curve from time 0 to infinity (AUC[0-﻿ ) was observed; however, this difference was less than the 2-fold range in AUC(0-∞) observed for the paediatric patients. 
V farmakokinetični študiji faze I so po intravenski uporabi med pediatričnimi in odraslimi bolniki ugotovili približno 25 % razliko v površini pod krivuljo od časa 0 do neskončnosti (AUC(0-∞)); vendar je bila ta razlika manjša od 2-kratnega razpona AUC(0-∞), ugotovljenega pri pediatričnih bolnikih.
Animal studies do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. 
Študije na živalih niso pokazale neposrednih škodljivih vplivov na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj.
Check the appearance of Aranesp. 
Preverite videz zdravila Aranesp.
Before you use an Aranesp pre-filled syringe with automatic needle guard, read this important information: 
Pred uporabo zdravila Aranesp v napolnjeni injekcijski brizgi z avtomatskim ščitnikom igle preberite te pomembne informacije:
INSERT the needle into skin. 
ZABODITE iglo v kožo.
980211) except for the adverse reaction of stroke which was identified as an adverse reaction in the TREAT 
980202 in 980211), poleg neželenega učinka možganska kap, ki je bil kot neželeni učinek prepoznan v študiji
The target haemoglobin concentration in two studies was > 13 g/dL; in the remaining three studies it was 12-14 g/dL. 
Ciljna koncentracija hemoglobina v teh dveh študijah je bila > 130 g/l, v preostalih treh pa od 120 do 140 g/l.
Active liver disease was an exclusion criteria in all studies of Aranesp, therefore no data are available from patients with impaired liver function. 
Aktivna bolezen jeter je bila v vseh študijah zdravila Aranesp merilo za nevključitev, zato o bolnikih z okvarjenim delovanjem jeter ni podatkov.
It is not known whether darbepoetin alfa is excreted in human milk. 
Ni znano, ali se darbepoetin alfa izloča v materino mleko.
Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to ensure that the lowest approved dose of Aranesp is used to maintain haemoglobin at a level that controls the symptoms of anaemia. 
Ko je terapevtski cilj pri posameznem bolniku dosežen, je treba odmerek zmanjšati za 25 do 50 % in tako zagotoviti uporabo najmanjšega odobrenega odmerka zdravila Aranesp, potrebnega za vzdrževanje takšne koncentracije hemoglobina, ki obvladuje simptome anemije.
Human erythropoietin is an endogenous glycoprotein hormone that is the primary regulator of erythropoiesis through specific interaction with the erythropoietin receptor on the erythroid progenitor cells in the bone marrow. 
Humani eritropoetin je endogen glikoproteinski hormon, ki primarno uravnava eritropoezo, in sicer preko specifične interakcije z eritropoetinskim receptorjem na eritroidnih matičnih celicah v kostnem mozgu.
What you need to know before you use Aranesp 
Kaj morate vedeti, preden boste uporabili zdravilo Aranesp
If a dose adjustment is required to maintain haemoglobin at the desired level, it is recommended that the dose is adjusted by approximately 25%. 
Če je za ohranitev hemoglobina na želeni ravni potrebna prilagoditev odmerka, je odmerek priporočljivo prilagoditi za približno 25 %.
Aranesp is given as a single injection, either once a week or once every three weeks, under your skin. 
Zdravilo Aranesp se daje v eni injekciji, bodisi enkrat na teden ali enkrat na tri tedne, in sicer pod kožo.
Red start button 
Rdeči sprožilni gumb
Aranesp treatment should be initiated by physicians experienced in the above mentioned indications. 
Zdravljenje z zdravilom Aranesp mora uvesti zdravnik, ki ima izkušnje z navedenima indikacijama.
• Bruising and bleeding at the site of injection 
• modrica in krvavitev na mestu injiciranja
- Misuse by healthy people can cause life-threatening problems with the heart or blood vessels. 
- Zloraba pri zdravih osebah lahko povzroči smrtno nevarne težave na srcu ali ožilju.
Source: Includes 5 randomised, double-blind, active-controlled studies (970200, 970235, 980117, 980202, and 
Vir: vključenih je 5 randomiziranih, dvojno slepih, aktivno kontroliranih študij (970200, 970235, 980117,
• The used pre-filled syringe should be disposed of in accordance with local requirements. 
• Uporabljeno napolnjeno injekcijsko brizgo zavrzite v skladu z lokalnimi predpisi.
Following blood tests, your doctor has decided you need Aranesp as your haemoglobin level is 10 g/dL or less. 
Glede na vaše krvne izvide je zdravnik presodil, da potrebujete zdravilo Aranesp, ker imate koncentracijo hemoglobina 100 g/l ali manj.
These included myelofibrosis and splenic hypertrophy as well as broadening of the ECG-QRS complex in dogs but no dysrhythmia and no effect on the QT interval were observed. 
Med temi učinki so bili mielofibroza, hipertrofija vranice ter razširitev kompleksa QRS na EKG pri psih, vendar brez motenj srčnega ritma in brez vpliva na interval QT.
Other medicines and Aranesp 
Druga zdravila in zdravilo Aranesp
Yellow safety guard 
Rumeni varnostni ščitnik
If this changes you will start on the same dose as you have been receiving and your doctor will take blood samples to make sure that your anaemia is still being managed correctly. 
Če se spremeni, boste začeli z enakim odmerkom, kot ste ga dobivali dotlej, zdravnik pa bo s kontrolami krvi preveril, ali je anemija še vedno ustrezno obvladana.
Yellow window (injection complete) 
Rumeno okence (injiciranje dokončano)
The haemoglobin should be measured every one or two weeks until it is stable. 
Hemoglobin morate kontrolirati na en ali dva tedna, dokler vrednost ni stabilna.
Clinical studies have demonstrated that darbepoetin alfa had similar effectiveness when administered as a single injection either once every three weeks, once every two weeks, or weekly without any increase in total dose requirements. 
Klinične študije so pokazale, da je darbepoetin alfa podobno učinkovit, če je uporabljen v posamični injekciji bodisi enkrat na tri tedne, enkrat na dva tedna ali vsak teden, brez potrebe po povečanju celotnega odmerka.
Remember: If you have any problems, please do not be afraid to ask your doctor or nurse for help and advice. 
Ne pozabite: če imate kakršne koli težave, brez obotavljanja prosite za pomoč in nasvet zdravnika ali medicinsko sestro.
Never inject Aranesp into a vein yourself. 
Zdravila Aranesp si nikdar sami ne injicirajte v veno.
• Sudden life-threatening allergic reactions (anaphylaxis) 
• nenadne smrtno nevarne alergijske reakcije (anafilaksija)
Due to its increased carbohydrate content the level of darbepoetin alfa in the circulation remains above the minimum stimulatory concentration for erythropoiesis for longer than the equivalent molar dose of r-HuEPO, allowing darbepoetin alfa to be administered less frequently to achieve the same biological response. 
Zaradi večje vsebnosti ogljikovih hidratov ostane koncentracija darbepoetina alfa v obtoku višja od najmanjše stimulacijske koncentracije za eritropoezo dalj časa kot po enakovrednem molarnem odmerku r-HuEPO; tako je mogoče z manj pogosto uporabo darbepoetina alfa doseči enak biološki odziv.
Prepare and clean your injection site. 
Pripravite in očistite mesto injiciranja.
Also, ulcers of mouth, throat, nose, genitals and eyes (red and swollen eyes) can occur. 
Pojavijo se lahko tudi razjede v ustih, žrelu, nosu, na spolovilih in očeh (rdeče in otekle oči).
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4). 
Metaanalize so tudi dosledno pokazale značilno večje relativno tveganje trombemboličnih dogodkov pri bolnikih z rakom, ki so dobivali rekombinantni humani eritropoetin (glejte poglavje 4.4).
After any dose or schedule adjustment the haemoglobin should be monitored every one or two weeks. 
Po vsaki prilagoditvi odmerka ali sheme morate hemoglobin kontrolirati na en ali dva tedna.
Part of the pre-filled pen may be broken even if you cannot see the break. 
V takšnem primeru je lahko del napolnjenega injekcijskega peresnika počen, čeprav ne vidite razpoke.
Upper arm Stomach area (abdomen) 
Nadlaket Področje želodca (trebuh)
In all cases, use a new pre-filled pen and contact your healthcare provider. 
V vseh teh primerih uporabite nov napolnjen injekcijski peresnik in kontaktirajte zdravstvenega delavca.
• A demonstration device 
• Demonstracijski pripomoček
In both groups, the dose was reduced by 40% of the previous dose (e.g., for first dose reduction, to 300 mcg in the once every three weeks group and 1.35 mcg/kg in the once weekly group) if haemoglobin increased by more than 1 g/dL in a 14-day period. 
V obeh skupinah so odmerek zmanjšali za 40 % predhodnega odmerka (npr. prvo zmanjšanje na 300 µg v skupini enkrat na tri tedne in na 1,35 µg/kg v skupini enkrat na teden), če se je hemoglobin v 14-dnevnem obdobju zvišal za več kot 10 g/l.
These studies have shown a consistent unexplained statistically significant excess mortality in patients who have anaemia associated with various common cancers who received recombinant human erythropoietin compared to controls. 
Te študije so pokazale dosledno, nepojasnjeno in statistično značilno večjo umrljivost med bolniki z anemijo zaradi različnih pogostih vrst raka, ki so dobivali rekombinantni humani eritropoetin, v primerjavi z bolniki v kontrolnih skupinah.
Check the expiry date on the pre-filled syringe label (EXP). 
Preverite datum izteka roka uporabnosti na nalepki napolnjene injekcijske brizge (EXP).
• A poster-size instructions for use (for patients/caregivers with diminished eyesight) - includes the instructions for use located in the package leaflet in a way that patients/caregivers with diminished eyesight are informed on how to handle the pen and administer Aranesp appropriately. 
• Navodila za uporabo v velikosti plakata (za bolnike/skrbnike z oslabljenim vidom) - vključujejo navodila za uporabo, ki so vključena v Navodilo za uporabo, da se bolniki/skrbniki z oslabljenim vidom seznanijo s tem, kako ravnati z injekcijskim peresnikom in si ustrezno dajati zdravilo Aranesp.
Since the liver is thought to be the principal route of elimination of darbepoetin alfa and r-HuEPO, Aranesp should be used with caution in patients with liver disease. 
Vendar jetra veljajo za glavno pot eliminacije darbepoetina alfa in r-HuEPO, zato morate zdravilo Aranesp pri bolnikih z boleznimi jeter uporabljati previdno.
This study was conducted in 705 anaemic patients with non-myeloid malignancies receiving multi-cycle chemotherapy. 
Študija je bila narejena pri 705 anemičnih bolnikih z nemieloičnimi malignomi, ki so dobivali več ciklusov kemoterapije.
- If you are a patient with chronic renal failure, and particularly if you do not respond properly to Aranesp, your doctor will check your dose of Aranesp because repeatedly increasing your dose of Aranesp if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death. 
- Če ste bolnik s kronično odpovedjo ledvic in še posebej, če se na zdravilo Aranesp ne odzovete primerno, vam bo zdravnik preverjal vaš odmerek zdravila Aranesp, ker lahko ponavljajoče se povečevanje odmerka zdravila Aranesp, če se na zdravilo ne odzovete, poveča tveganje za težave s srcem ali ožiljem in vam lahko poveča tveganje za srčni infarkt, možgansko kap in smrt.
• 500 micrograms once every three weeks (6.75 micrograms of Aranesp per kilogram of your body weight), or 
• 500 mikrogramov enkrat na tri tedne (6,75 mikrogramov zdravila Aranesp na kilogram telesne mase) ali
Do not inject into areas where the skin is tender, bruised, red, or hard. 
Ne injicirajte v predele, kjer je koža občutljiva, podpluta, pordela ali zatrdela.
There was an expected moderate (< 2 fold) increase in serum concentration as steady state was approached, but no unexpected accumulation upon repeated administration. 
Ko se je bližalo stanje dinamičnega ravnovesja, je prišlo do pričakovanega zmernega (< 2-kratnega) povečanja koncentracije v serumu, ni pa bilo med ponavljajočo uporabo nobenega nepričakovanega kopičenja.
Incidence of adverse reactions from controlled clinical studies and post-marketing experience are: 
Pogostnosti neželenih učinkov, zabeleženih v kontroliranih kliničnih študijah in v obdobju trženja zdravila, so:
Per the Guideline on Summary of Product 
V skladu z dokumentom Guideline on Summary of
The best places to inject yourself are the top of your thighs and the abdomen. 
Najprimernejši mesti za samoinjiciranje sta zgornji del stegen in trebuh.
These can appear as reddish target-like macules or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms. 
Ti se lahko pojavijo kot rdečkaste, tarčam podobne kožne spremembe ali krožne lehe, pogosto z osrednjim mehurjem na trupu, lupljenje kože, razjede v ustih, žrelu, nosu, na spolovilih in očeh, pred tem se lahko pojavijo zvišana telesna temperatura in/ali gripi podobni simptomi.
This was a non inferiority study designed to rule out a 15% risk increase in tumour progression or death of epoetin alfa plus standard of care (SOC) as compared with SOC alone. 
To študijo neinferiornosti so zasnovali za izključitev 15 % povečanja tveganja napredovanja tumorja ali smrti pri zdravljenju z epoetinom alfa in standardno oskrbo v primerjavi z zdravljenjem samo s standardno oskrbo.
If typical causes of non-response are excluded, and the patient has reticulocytopenia, an examination of the bone marrow should be considered. 
Če ste izključili tipične vzroke neodzivnosti, bolnik pa ima retikulocitopenijo, pride v poštev pregled kostnega mozga.
- The active substance is darbepoetin alfa, r-HuEPO (erythropoietin produced by genetechnology). 
- Učinkovina je darbepoetin alfa, r-HuEPO (eritropoetin, pridobljen z gensko tehnologijo).
Important: It is important to keep your skin stretched or pinched while injecting. 
Pomembno: Pomembno je, da kožo med injiciranjem držite raztegnjeno ali stisnjeno.
D Prepare and clean your injection site. 
D Pripravite in očistite mesto injiciranja.
Clearance of darbepoetin alfa is 1.9 mL/hr/kg (SD 0.56) and the volume of distribution (Vss) is approximately equal to plasma volume (50 mL/kg). 
Očistek darbepoetina alfa je 1,9 ml/h/kg (standardni odklon 0,56), volumen porazdelitve (Vss) pa je približno enak volumnu plazme (50 ml/kg).
If you have chronic renal failure 
Če imate kronično odpoved ledvic
Therapy with Aranesp can result in polycythaemia if the haemoglobin is not carefully monitored and the dose appropriately adjusted. 
Zdravljenje z zdravilom Aranesp lahko povzroči policitemijo, če koncentracija hemoglobina ni natančno nadzorovana in odmerek zdravila ustrezno prilagojen.
Healthcare professionals prescribing Aranesp pre-filled pen will be provided educational materials to facilitate training patients on the correct self-administration of Aranesp. 
Zdravstvenim delavcem, ki predpisujejo zdravilo Aranesp v obliki napolnjenega injekcijskega peresnika, bo zagotovljeno izobraževalno gradivo kot pomoč pri usposabljanju bolnikov o pravilnem samoinjiciranju zdravila Aranesp.
There are additional educational materials available to train you on how to self administer Aranesp pre-filled pen, a dummy demonstration device and a poster-size instructions for use for patients/caregivers with diminished eyesight. 
Na voljo je tudi dodatno izobraževalno gradivo, ki vam omogoča, da se usposobite za samostojno injiciranje zdravila Aranesp v obliki napolnjenega injekcijskega peresnika, demonstracijski pripomoček brez učinkovine in navodila za uporabo v velikosti plakata za bolnike/negovalce z zmanjšanim vidom.
Step 1: Prepare A Remove the pre-filled syringe tray from the package and gather the supplies needed for your injection: alcohol wipes, a cotton ball or gauze pad, a plaster and a sharps disposal container (not included). 
1. korak: Priprava A Vzemite podlogo z napolnjeno injekcijsko brizgo iz pakiranja in pripravite opremo, potrebno za injiciranje: alkoholne zložence, kosem vate ali zloženec gaze, obliž in vsebnik za ostre odpadke (ni priloženo).
• 2.25 micrograms (once weekly) of Aranesp per kilogram of your body weight. 
• 2,25 mikrogramov (enkrat na teden) zdravila Aranesp na kilogram telesne mase.
Darbepoetin alfa is produced by gene-technology in Chinese Hamster Ovary Cells (CHO-K1). 
Darbepoetin alfa je pridobljen z gensko tehnologijo v ovarijskih celicah kitajskega hrčka (CHO-K1).